BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:U.S. CDMRP – Autism Research Program | Research Funding
DTSTART;VALUE=DATE:20230329
DTSTAMP:20260415T032511Z
UID:39987e49d582fbac8c8432efe2985b432b3d15d1bb86fe970052030c
CATEGORIES:Call for proposal
DESCRIPTION:Aim: Through the Congressionally Directed Medical Research Pro
 gram (CDMRP)\, the Department of Defense is announcing the Autism Research
  Program (ARP) Awards.\n\nAll applications for ARP funding must specifical
 ly address at least one of the Areas of Interest as directed by Congress a
 nd have direct relevance to military health\; see the end of this advertis
 ement for a list of these Areas.\nSeveral award programs are available:\n\
 n	The Idea Development Award supports the development of innovative\, high
 -risk/high-reward research that could lead to critical discoveries or majo
 r advancements that will accelerate progress in improving outcomes for ind
 ividuals with ASD.\n	The Career Development Awards supports early-career\,
  independent investigators and/or the transition of established investigat
 ors from other research fields to conduct innovative\, high-impact ideas o
 r early-phase\, proof-of-principle clinical trials with the potential to h
 ave major impact on ASD.\n	The Clinical Trial Awards supports the rapid im
 plementation of clinical trials with the potential to have a significant i
 mpact on the treatment or management of ASD.\n\n\nFunding:       Idea
  Development Award – max. $550\,000\nCareer Development Award – max. $
 550\,000\nClinical Trial Award – $1.9M - $2.2M\n\nDuration:      Ide
 a Development Award – 3 years\nCareer Development Award – 3 years\nCli
 nical Trial Award – 4  years\n\nEligibility: Applicants from internatio
 nal organizations or institutions are eligible to apply\, and there are no
  citizenship restrictions. All investigators at or below the level of assi
 stant professor (or equivalent) are eligible for the Career Development Aw
 ard.  All investigators at or above the level of assistant professor (or 
 equivalent) are eligible for the Idea Development Award and Clinical Trial
  Award.\n\nHow to Apply: Pre-applications are submitted through the eBRAP 
 platform. They should contain contact information\, a letter of intent\, a
 nd a list of collaborators and key personnel as suggested on the platform.
  Full applications will be made via a Grants.gov workspace. Application pa
 ckages can be downloaded from Grants.gov at any time.\n\nGrants.gov Fundin
 g Opportunity Numbers:\n\n\n	Idea Development Award – HT9425-23-ARP-IDA\
 n	Career Development Award – HT9425-23-ARP-CDA\n	Clinical Trial Award 
 – HT9425-23-ARP-CTA\n\n\nPre-Application Deadline:           Ap
 ril 19\, 2023 (5:00 p.m. Eastern time)\nFull Application Deadline:    
         July 20\, 2023\n\nFurther information\n\n\n	To find the ful
 l program announcements\, use the opportunity-specific links above to conn
 ect to Grants.gov\n	For questions about the eBRAP or Grants.gov platforms\
 , contact the Research Office.\n\n\nFY23 ARP Career Development Award Area
 s of Interest\n\n\n	Assessment of novel therapeutics using valid preclinic
 al models\n	Create tools and strategies to increase the speed with which e
 vidence-based practices are deployed in community-based settings\n	Cultura
 l\, socioeconomic\, and gender factors in diagnosis\, treatment efficacy\,
  delivery\, and access to services\n	Development of healthcare provider-fo
 cused training or tools to improve healthcare delivery for autistic indivi
 duals across the life span and the continuum of care (i.e.\, primary care\
 , urgent/emergent care\, and disaster relief)\n	Environmental risk factors
 \n	Factors impacting quality of life during geographic relocation\, such a
 s military permanent change of station\n	Factors promoting success in key 
 transitions to independence for individuals living with ASD\n	Improve diag
 nosis and access to services across the life span\n	Interventions to suppo
 rt ASD adults\, including transition to adulthood\, mid-life\, and late li
 fe needs\n	Long-term treatment outcomes from previous clinical trials for 
 ASD core symptoms or to alleviate co-occurring conditions\n	Mechanisms of 
 heterogeneous clinical expression of ASD\n	Mechanisms underlying sex diffe
 rences (i.e.\, prevalence\, biological mechanisms\, phenotypic expression\
 , core and comorbid syndrome expression and outcomes\, developmental traje
 ctories\, diagnosis\, and treatment response)\n	Mechanisms underlying cond
 itions co-occurring with ASD (e.g.\, sleep disturbances\,\n	gastrointestin
 al issues\, inflammation\, aggression\, depression\, anxiety\, attention d
 eficit\, and seizures)\n	(New for FY23) Mental health issues (such as grie
 f\, masking\, suicide risk\, trauma\, etc.) or disorders in autistic indiv
 iduals\n	 \n	Tests of implementation strategies to increase use of eviden
 ce-based practices\n	(New for FY23) Understanding heterogeneity in treatme
 nt response\, including identification of psychosocial or biological facto
 rs that (1) impact treatment outcomes or (2) can be used to prospectively 
 identify treatments that are most likely to benefit particular subgroups o
 f individuals.\n	Understanding key factors to support ASD adults\, includi
 ng transition to adulthood\n\n(New for FY23) Understanding physical health
  and related issues in aging autistic adults including cardiovascular issu
 es\, joint pain\, asthm
LOCATION:
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR